The Clinical Core performs comprehensive clinical and neuropsychological patient evaluations, coordinates data transfer to the Data Management Core, and conducts longitudinal follow up of elders with normal cognition, mild cognitive impairment and with Alzheimer's disease and other dementias. The Clinical Core coordinates recruitment of subjects for the Mount Sinai ADRC, the Alzheimer's Disease Cooperative Study (ADCS), the National Alzheimer's Coordinating Center (NACC) and other National Institute of Health funded studies, and non-funded pilot studies. In its ongoing efforts to serve a diverse population, the Clinical Core maintains a Satellite Diagnostic and Treatment Clinic for the recruiment of minorty poulations. This Core works on the development of method for research in Alzheimer's and provides training to a wide range of researchers to assist in the collection of data in related areas. The Core approaches all participants for the autopsy program. Antemortem clinical information on all autopsied cases is provided to the Neuropathology Core through the data management core. Educational and outreach activities are conducted in conjunction with the Education Information Transfer Core.
Alzheimer's disease is expected to claim 8 million victims within the next 25 years. There is no means of preventing or reversing the disease. The actiivtes proposed in this application will provide research particpants for entire spectrum of studies needed to understand the mechanisms of the disease and with which to develop effective treatments. These studies, ranging from molecular studies of tissue specmens to imaging to clinical trials all require the richly charcaterized subjects provided by the Core.
|Amrock, Levana G; Deiner, Stacie (2014) The implication of frailty on preoperative risk assessment. Curr Opin Anaesthesiol 27:330-5|
|Mitsis, Effie M; Bender, Heidi A; Kostakoglu, Lale et al. (2014) A consecutive case series experience with [18?F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener 9:10|
|Lunnon, Katie; Smith, Rebecca; Hannon, Eilis et al. (2014) Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci 17:1164-70|
|Dekosky, Steven T; Gandy, Sam (2014) Environmental exposures and the risk for Alzheimer disease: can we identify the smoking guns? JAMA Neurol 71:273-5|
|Roussos, Panos; Mitchell, Amanda C; Voloudakis, Georgios et al. (2014) A role for noncoding variation in schizophrenia. Cell Rep 9:1417-29|
|Ravona-Springer, Ramit; Heymann, Anthony; Schmeidler, James et al. (2014) The ApoE4 genotype modifies the relationship of long-term glycemic control with cognitive functioning in elderly with type 2 diabetes. Eur Neuropsychopharmacol 24:1303-8|
|Jun, Gyungah; Asai, Hirohide; Zeldich, Ella et al. (2014) PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation. Ann Neurol 76:379-92|
|Neugroschl, Judith; Sano, Mary; Luo, Xiaodong et al. (2014) Why They Stay: Understanding Research Participant Retention in Studies of Aging, Cognitive Impairment and Dementia. J Gerontol Geriatr Res 3:|
|Babi?, Mirjana; Svob Štrac, Dubravka; Mück-Šeler, Dorotea et al. (2014) Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J 55:347-65|
|Greenbaum, Lior; Springer, Ramit Ravona; Lutz, Michael W et al. (2014) The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes. Eur Neuropsychopharmacol 24:1492-9|
Showing the most recent 10 out of 255 publications